Information

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy. If, after doing this, organisations still wish to consider ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when NICE guidance is unavailable.

NICE will review the position at any point if the company decides that it wants to make a full submission.

ISBN: 978-1-4731-2423-3

  • National Institute for Health and Care Excellence (NICE)